JP2015521728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521728A5 JP2015521728A5 JP2015516504A JP2015516504A JP2015521728A5 JP 2015521728 A5 JP2015521728 A5 JP 2015521728A5 JP 2015516504 A JP2015516504 A JP 2015516504A JP 2015516504 A JP2015516504 A JP 2015516504A JP 2015521728 A5 JP2015521728 A5 JP 2015521728A5
- Authority
- JP
- Japan
- Prior art keywords
- expression level
- compound
- protein
- genotoxic
- ser1981
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 230000001738 genotoxic effect Effects 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 231100000024 genotoxic Toxicity 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 claims 2
- 101150033270 Gadd45a gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 231100000025 genetic toxicology Toxicity 0.000 claims 2
- 238000013537 high throughput screening Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 108010034798 CDC2 Protein Kinase Proteins 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 claims 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 claims 1
- 108010019243 Checkpoint Kinase 2 Proteins 0.000 claims 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
- 101710157567 Cyclin-dependent kinase inhibitor 1 Proteins 0.000 claims 1
- 230000005778 DNA damage Effects 0.000 claims 1
- 231100000277 DNA damage Toxicity 0.000 claims 1
- 102100030013 Endoribonuclease Human genes 0.000 claims 1
- 101710199605 Endoribonuclease Proteins 0.000 claims 1
- 102000017286 Histone H2A Human genes 0.000 claims 1
- 108050005231 Histone H2A Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003831 deregulation Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000003125 immunofluorescent labeling Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- -1 p-p53 (Ser15 ) Proteins 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659024P | 2012-06-13 | 2012-06-13 | |
| US61/659,024 | 2012-06-13 | ||
| PCT/EP2013/001575 WO2013185884A1 (en) | 2012-06-13 | 2013-05-28 | Protein expression analyses for identifying genotoxic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521728A JP2015521728A (ja) | 2015-07-30 |
| JP2015521728A5 true JP2015521728A5 (enExample) | 2016-07-21 |
| JP6301915B2 JP6301915B2 (ja) | 2018-03-28 |
Family
ID=48536789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516504A Expired - Fee Related JP6301915B2 (ja) | 2012-06-13 | 2013-05-28 | 遺伝毒性化合物を同定するためのタンパク質発現分析 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150140123A1 (enExample) |
| EP (1) | EP2861985B1 (enExample) |
| JP (1) | JP6301915B2 (enExample) |
| CN (1) | CN104364649B (enExample) |
| AU (1) | AU2013276950B2 (enExample) |
| CA (1) | CA2876402A1 (enExample) |
| ES (1) | ES2660131T3 (enExample) |
| IL (1) | IL236195B (enExample) |
| WO (1) | WO2013185884A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9470694B2 (en) | 2013-03-09 | 2016-10-18 | Litron Laboratories Ltd. | Simplified nuclei analysis platform and biomarker matrix that supports genotoxic mode of action determinations |
| WO2014152873A1 (en) * | 2013-03-14 | 2014-09-25 | Pioma Inc. | Microvesicle histone h2ax as a biomarker for genotoxic stress |
| CN104515760B (zh) * | 2014-12-17 | 2017-10-31 | 深圳市纳观生物有限公司 | 双色荧光定位超分辨率生物显微方法及系统 |
| WO2017145816A1 (ja) * | 2016-02-24 | 2017-08-31 | ソニー株式会社 | 光学測定器、フローサイトメータ、および放射線計数器 |
| CN107159327B (zh) | 2017-05-17 | 2019-04-19 | 京东方科技集团股份有限公司 | 一种生物检测芯片及其检测方法 |
| CN110333207A (zh) * | 2019-06-25 | 2019-10-15 | 中国人民解放军陆军军医大学第一附属医院 | CREB在Ang-2调节VEGFR2表达中分析方法 |
| WO2021102420A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Interferon signaling as a cancer biomarker |
| CN112680498A (zh) * | 2020-12-28 | 2021-04-20 | 华南理工大学 | 一种遗传毒性物质的高通量筛查方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0411198D0 (en) * | 2004-05-20 | 2004-06-23 | Gentronix Ltd | Genotoxic testing |
| ATE480642T1 (de) * | 2004-11-24 | 2010-09-15 | Hoffmann La Roche | Verfahren zur bestimmung von genotoxizität |
| CN101903774A (zh) * | 2007-12-20 | 2010-12-01 | 弗·哈夫曼-拉罗切有限公司 | 预测基因毒性 |
| GB0905410D0 (en) * | 2009-03-28 | 2009-05-13 | Gentronix Ltd | Genotoxicity testing |
| DE102010024898B4 (de) * | 2010-06-24 | 2012-10-25 | Merck Patent Gmbh | Genexpressionsanalysen zur Charakterisierung und Identifizierung genotoxischer Verbindungen |
-
2013
- 2013-05-28 CA CA2876402A patent/CA2876402A1/en not_active Abandoned
- 2013-05-28 WO PCT/EP2013/001575 patent/WO2013185884A1/en not_active Ceased
- 2013-05-28 CN CN201380030301.2A patent/CN104364649B/zh not_active Expired - Fee Related
- 2013-05-28 AU AU2013276950A patent/AU2013276950B2/en not_active Ceased
- 2013-05-28 EP EP13725576.6A patent/EP2861985B1/en not_active Not-in-force
- 2013-05-28 US US14/405,626 patent/US20150140123A1/en not_active Abandoned
- 2013-05-28 JP JP2015516504A patent/JP6301915B2/ja not_active Expired - Fee Related
- 2013-05-28 ES ES13725576.6T patent/ES2660131T3/es active Active
-
2014
- 2014-12-11 IL IL236195A patent/IL236195B/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521728A5 (enExample) | ||
| Kalu et al. | Genomic characterization of human papillomavirus-positive and-negative human squamous cell cancer cell lines | |
| El-Shinawi et al. | Human cytomegalovirus infection enhances NF-κB/p65 signaling in inflammatory breast cancer patients | |
| Wisniewski et al. | High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers | |
| Zhang et al. | Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer | |
| Hong et al. | HPV status of oropharyngeal cancer by combination HPV DNA/p16 testing: biological relevance of discordant results | |
| Kuo et al. | High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma | |
| She et al. | C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma | |
| Xie et al. | Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a | |
| JP2016500110A5 (enExample) | ||
| Ferrin et al. | Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV‐infected cirrhotic patients by 2‐D DIGE | |
| Liu et al. | Human papillomavirus as a favorable prognostic factor in a subset of head and neck squamous cell carcinomas: A meta‐analysis | |
| Pluder et al. | Low-dose irradiation causes rapid alterations to the proteome of the human endothelial cell line EA. hy926 | |
| Zergoun et al. | IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients | |
| Higgs et al. | Downregulation of Gadd45β expression by hepatitis C virus leads to defective cell cycle arrest | |
| Qin et al. | The effect of SHH-Gli signaling pathway on the synovial fibroblast proliferation in rheumatoid arthritis | |
| Qiu et al. | Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells | |
| Gusho et al. | Human papillomaviruses target the DNA damage repair and innate immune response pathways to allow for persistent infection | |
| Liao et al. | Clinical significance and gene expression study of human hepatic stellate cells in HBV related-hepatocellular carcinoma | |
| Li et al. | Expression of PGAM1 in renal clear cell carcinoma and its clinical significance | |
| Zhu et al. | Hepatitis B virus X protein driven alpha fetoprotein expression to promote malignant behaviors of normal liver cells and hepatoma cells | |
| Stangherlin et al. | Human cytomegalovirus DNA quantification and gene expression in gliomas of different grades | |
| Yang et al. | Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells | |
| Koh et al. | Epstein‐Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma | |
| Graf et al. | New insight into the phosphorylation-regulated intranuclear localization of human cytomegalovirus pUL69 mediated by cyclin-dependent kinases (CDKs) and viral CDK orthologue pUL97 |